KRAS and pancreatic adenocarcinoma: In order to verify the observation in Supplementary Table 2 and 3 showing enrichment of mitotic/cell cycle pathways in UCSF lung tumors with a low KRAS4A/KRAS4B ratio, we separated the available TCGA lung carcinoma samples into KRAS4A/KRAS4B high (n = 7) and low (n = 7) groups and pancreatic adenocarcinoma samples into KRAS4A/KRAS4B high (n = 9) and low (n = 9) groups and examined the total RNASeq data for differences in these gene expression pathways.